TY  - JOUR
AU  - Asensio Lopez, Maria Del Carmen
AU  - Lax, Antonio
AU  - Hernandez Vicente, Alvaro
AU  - Saura Guillen, Elena
AU  - Hernandez-Martinez, Antonio
AU  - Fernandez Del Palacio, Maria Josefa
AU  - Bayes-Genis, Antoni
AU  - Pascual-Figal, Domingo A
PY  - 2020
DO  - 10.1038/s41598-020-70454-8
SN  - 2045-2322
UR  - http://hdl.handle.net/20.500.12105/12869
AB  - Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have shown to prevent heart failure progression, although the mechanisms remain poorly understood. Here we evaluated the effect of empagliflozin (EMPA, SGLT2i) in cardiac remodeling after myocardial...
LA  - eng
PB  - Nature Publishing Group
KW  - Animals
KW  - Benzhydryl Compounds
KW  - Diabetes Mellitus, Experimental
KW  - GTP Cyclohydrolase
KW  - Glucosides
KW  - Male
KW  - Myocardial Infarction
KW  - Rats
KW  - Rats, Wistar
KW  - Sodium-Glucose Transporter 2 Inhibitors
KW  - Ventricular Dysfunction, Left
KW  - Ventricular Remodeling
TI  - Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status.
TY  - journal article
ER  -